|
Welcome to the web pages of Øyvind S. Bruland
On this web site you will find information about my scientific work within cancer research,
as well as other activities.
My clinical experience and research are mainly devoted to primary bone and soft tissue cancers (sarcomas) and skeletal metastases from prostate cancer and breast cancer. In particular, targeted radionuclide therapy, e.g. Alpharadin (Algeta), based on Radium-223, is currently at center stage.
Seksjonsoverlege Øyvind Bruland
Onkologisk avd.
Det Norske Radiumhospital
N-0310 OSLO
|
Professor of Clinical Oncology
Department of Medical Oncology & Radiotherapy
The Norwegian Radium Hospital
N-0310 Oslo, NORWAY |
Recent updates and publications
Life with Cancer
We compiled this book to shed light on several aspects of cancer - a disease that engenders more fear and uncertainty than most other prevalent diseases. In the popular science tradition, this book discusses causes and treatments of cancer, late effects that may develop after a cure is effected, some new inroads being made in cancer research, and we meet cancer patients and relatives in moving encounters that offer precious insight. Click here for more information on this illustrated book, with its content, foreword, author biographies and a PDF of my own chapter: "Cancer - Causes and Treatment." [19.02.08]
Publication in Lancet Oncology
Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.Lancet Oncol. 2007 Jul;8(7):587-94. Download article in PDF format
[05.11.07 10:10]
Publication in Blood, 2007
Our group have recently published a translational study on alpha-particle based radiomimmunotherapy in the high-impact journal Blood You may view a pdf of the paper here
[19.11.07 13:49]
Alpharadin (Radium-223) - Further positive results
Some key issues to understand this promising new treatment strategy
- Epidemiology
- Tumor biology
- Radio biology
- Target distribution
- Phase 3 + Video
Click here to view the presentation (PDF format)
In this review - printed in the September 2008 issue of "Current Radiopharmaceuticals" - we present the evolution from radiochemical discovery to clinical applications of radium-223 (Alpharadin). Click here to view the table of contents (PDF rormat) Click here do download a pdf of the manuscript Results from a Phase II randomized clinical trial of the novel alpha-emitting bone-seeker Alpharadin™ in patients with late-stage hormone-refractory prostate cancer (HRPC), including significant survival data, were presented at the American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium (Orlando, Florida, USA February 22-24, 2007). You may view the poster here ( Hyperlink to pdf)
[20.11.08 14:52]
Treatment of bone metastasis
[26.10.06 12:10]
Skeletal metastases and radiotherapy
In the 8th edition of the ASBMR-primer (American Society of Bone and Mineral Research), published November, 2008, we have reviewed the current practice of external beam radiotherapy in skeletal metastases. Guidelines are presented on how best to select patients that should be offered a single fraction of 8Gy and those that should be given fractionated radiotherapy. Futhermore, the use of bone-seeking radiopharaceuticals is also discussed. Click here for a pdf of the paper We have also published results in "the green journal" from a randomised phase III clinical trial involving 376 patients with painful skeletal metastases form various malignancies. A comparison between a single dose (8Gy) and fractionated radiotherapy (3Gy x 10)revealed no major differences in the palliative benefit and shows that 8Gy x 1; with an option for re-treatment, should be standard management policy for these patients. Click here to download the article (PDF format).
[19.11.08 14:23]
|
|
|
Print this page